kresmion.
Pull a receipt

Citius Pharmaceuticals, Inc. (CTXR)

Sector
Healthcare
Industry
Biotechnology
Last price
$0.55
As of

Kresmion compiles this page from CTXR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Citius Pharmaceuticals, Inc. (CTXR): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.

As of . Source: SEC EDGAR filings for CTXR. Method and limitations.

COMPANY DOSSIER

See the full CTXR dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for CTXR on one page. Preview it with sample data, then open it live with a free account.

Preview the CTXR dossier

Active events for CTXR

FREE, NO ACCOUNT

Every event on CTXR, as it fires

You are seeing 5 of 7 events recorded on CTXR since 2026-05-24.

The five above landed across 4 days. The other 2 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

CTXR positions held by the managers we follow (2026Q2)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
CITADEL ADVISORS LLC FundCUSIP 17322U306 · 2026Q2$76K0.00%
TWO SIGMA INVESTMENTS, LP FundCUSIP 17322U306 · 2026Q2$11K0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, CTXR

Going concern statement

CTXR's 10-Q filed Aug 14, 2026 states:

…additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on CTXR

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in CTXR on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CTXR in the last 180 days.

Upstream: SEC EDGAR filings for CTXR

Kresmion, "Citius Pharmaceuticals, Inc. (CTXR) institutional holdings and SEC filings", data as of 2026-11-04, https://kresmion.com/research/CTXR. Upstream data: SEC EDGAR filings for CTXR.

Link to this data (HTML):

<a href="https://kresmion.com/research/CTXR">Citius Pharmaceuticals, Inc. (CTXR) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow CTXR on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CTXR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the CTXR dossier
Share

The CTXR intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.